This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

BNMS 2024

In the PSMA era, is there still a place for Xofigo▼ (radium-223 dichloride) in the management of advanced prostate cancer?

Xofigo Header Image

An on demand video of the Bayer-sponsored symposium at the British Nuclear Medicine Society (BNMS) Spring Meeting 2024, which took place in Belfast on the 15th May 2024. In this session Professor Joe O'Sullivan, Clinical Oncologist, Northern Ireland Cancer Centre articulates the potential impact of radionuclide therapies on managing prostate cancer, with a specific focus on radium-223.

This symposium was organised and funded by Bayer.

Xofigo▼ Prescribing Information

NUBEQA® (darolutamide) Prescribing Information

Speakers
    • Professor Joe Sullivan
      Professor Joe O'Sullivan

    Professor Joe O'Sullivan, a distinguished oncologist specialising in prostate cancer, holds the position of Professor of Radiation Oncology at Queen's University Belfast. His fervor lies in the care of prostate cancer patients, and he is deeply motivated to enhance outcomes across all facets of this illness while actively pioneering novel therapeutic approaches, particularly within the domains of External Beam Radiation Therapy and Bone-seeking radionuclide therapy.

Evolving mCRPC treatment landscape in 2023
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0505, February2024

Abbreviations: PSMA; prostate-specific membrane antigen

 

PP-XOF-GB-0598 | January 2025